Peptide News Digest

#440-Million

2 stories

Industry · View digest

Hims & Hers Health (NYSE: HIMS) Q2 2026 Earnings Preview for Monday August 10 After Market Close With Koyfin Consensus Estimates of $730.12 Million Revenue (+20% YoY), $47.26 Million EBITDA (+7% YoY), and $0.11 Adjusted Diluted EPS; Analyst Focus on the Peptide-Compounding Revenue Trajectory (Leerink Estimates $440 Million Peptide Sales in 2026 Representing Roughly 15% of the Projected 2026 Revenue Midpoint) and the Post-PCAC Investor Narrative Following the July 23-24 FDA Advisory Panel 6-of-7 Vote Recommending BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the Section 503A Bulks List (DSIP Rejected)

Hims & Hers Health (NYSE: HIMS) reports Q2 2026 earnings Monday August 10, 2026 after market close, with a live conference call scheduled for 5:00 PM ET. Koyfin consensus estimates: revenue of $730.12 million (+20% year-over-year), $47.26 million EBITDA (+7% YoY), and $0.11 adjusted diluted EPS. Analyst focus areas beyond the top-line numbers: the peptide-compounding revenue trajectory following the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 vote recommending BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the Section 503A Bulks List (DSIP was rejected); the branded GLP-1 supply migration through the Novo Nordisk Wegovy/Ozempic and Eli Lilly Zepbound/Mounjaro commercial partnerships since Q1 2026; and management commentary on the FDA rulemaking timeline (typically 12-24 months per PCAC-recommended substance) that gates when the July 23-24 PCAC recommendation actually translates into new compounded-peptide revenue lines. Leerink analysts estimate Hims peptide sales at approximately $440 million in 2026, representing roughly 15% of the projected 2026 revenue midpoint; Truist analysts have cautioned that substantial peptide revenue is unlikely before 2028 even with the PCAC advisory support. Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC public-comment testimony (which reportedly moved several undecided panelists on the harm-reduction argument for legal 503A compounded peptides) added a public-facing dimension to the Hims peptide strategy that will likely be referenced on the earnings call.

Industry · View digest

Post-PCAC Analyst Perspective on Hims & Hers Health (NYSE: HIMS): BofA Securities Raised Price Target to $36 and Canaccord Genuity Raised to $40 on the Peptide-Compounding Opportunity Estimated at Approximately $440 Million in 2027 Sales From the Four Recommended Compounding Peptides, While Truist Held at $23 Citing the 6-18 Month FDA Rulemaking Timeline and Uninsured-Patient Concerns; Peptide Catalyst Lift Tempered by the Advisory-Vote Nature of the July 23-24 PCAC 6-of-7 Outcome Because Compounding Pharmacies Still Cannot Legally Prepare BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon Under Section 503A Today

Post-PCAC analyst coverage of Hims & Hers Health (NYSE: HIMS) split on the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 outcome. BofA Securities raised its price target to $36 on the peptide-compounding opportunity, and Canaccord Genuity raised to $40, both citing the July 23-24 PCAC vote and the Hims & Hers acquired California peptide manufacturing facility. Analysts estimate the four Day-1 recommended peptides (BPC-157, KPV, TB-500, MOTS-c) could generate approximately $440 million in Hims & Hers sales by 2027 if the FDA follows through with 503A rulemaking. Truist Securities held at $23 citing the 6-18 month FDA rulemaking timeline and continued uninsured-patient exposure. Barclays sits at $39 (Novo Nordisk partnership thesis). The peptide catalyst lift is tempered by the advisory-vote nature of the PCAC outcome: compounding pharmacies still cannot legally prepare BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon under Section 503A today because none of the six substances are on the 503A Bulks List. FDA rulemaking to add each substance takes 6-18 months from the date the agency decides to act. Hims shares closed near $28.50 last week after briefly rallying above $35 on the initial vote outcome.